{"id":"high-dose-buprenorphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine binds to mu-opioid receptors with high affinity but partial agonist activity, meaning it produces a ceiling effect that limits respiratory depression risk. At higher doses, it achieves greater analgesic potency and more effective suppression of opioid withdrawal symptoms while maintaining this safety profile. This makes high-dose formulations suitable for severe pain management and opioid use disorder treatment in patients requiring stronger therapeutic effects.","oneSentence":"High-dose buprenorphine is a partial mu-opioid receptor agonist that provides stronger analgesia and opioid dependence treatment at elevated doses compared to standard formulations.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:16.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain"},{"name":"Opioid use disorder"}]},"trialDetails":[{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT06726200","phase":"EARLY_PHASE1","title":"A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use","status":"RECRUITING","sponsor":"Rachel R. Luba","startDate":"2026-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT06005662","phase":"PHASE2","title":"Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2027-04","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT04995029","phase":"PHASE4","title":"Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2021-10-26","conditions":"Moderate to Severe Opioid-use Disorder","enrollment":785},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT06316830","phase":"PHASE2, PHASE3","title":"Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose","status":"RECRUITING","sponsor":"Rhode Island Hospital","startDate":"2025-01-06","conditions":"Opioid Use Disorder","enrollment":250},{"nctId":"NCT05589181","phase":"PHASE3","title":"High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-04-06","conditions":"Opioid Use Disorder","enrollment":140},{"nctId":"NCT06051890","phase":"PHASE4","title":"Assessing Optimal XRB Initiation Points in Jail","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-06-02","conditions":"Opioid Use Disorder","enrollment":200},{"nctId":"NCT06379984","phase":"PHASE2","title":"Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-05-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT05944952","phase":"PHASE4","title":"Low-dose Versus a High-dose Sublingual Buprenorphine Induction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2024-06-20","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT06067737","phase":"PHASE2","title":"Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-02-08","conditions":"Opioid Use Disorder","enrollment":90},{"nctId":"NCT03918850","phase":"PHASE3","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":140},{"nctId":"NCT04363320","phase":"NA","title":"Fostering MAT Use in Justice Populations","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2020-07-30","conditions":"Opioid-use Disorder, Recidivism","enrollment":256},{"nctId":"NCT06494904","phase":"PHASE3","title":"Standard Versus High Dose ED-Initiated Buprenorphine Induction","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-12-06","conditions":"Opioid Use Disorder","enrollment":360},{"nctId":"NCT03747341","phase":"PHASE1","title":"Buprenorphine-Fentanyl Interaction Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2018-03-22","conditions":"Healthy, Opioid Use","enrollment":22},{"nctId":"NCT06772324","phase":"NA","title":"An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders","status":"NOT_YET_RECRUITING","sponsor":"Peking University Sixth Hospital","startDate":"2025-01","conditions":"Autism Spectrum Disorder","enrollment":60},{"nctId":"NCT04794790","phase":"EARLY_PHASE1","title":"Buprenorphine Induction for Fentanyl Dependent Opioid Users","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-05-09","conditions":"Opioid Dependence Fentanyl","enrollment":""},{"nctId":"NCT00723697","phase":"","title":"Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2007-05","conditions":"Buprenorphine, Naloxone, Opiate-related Disorders","enrollment":1307},{"nctId":"NCT02187198","phase":"PHASE3","title":"Buprenorphine Treatment for Opioid Dependence","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-03","conditions":"Opioid Dependence","enrollment":9},{"nctId":"NCT00929253","phase":"NA","title":"Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2007-09","conditions":"Opiate Addiction","enrollment":170},{"nctId":"NCT03156907","phase":"PHASE2","title":"High Dosage Buprenorphine as a Drug Strategy Withdrawal Assistance of Analgesics Opioid","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2017-09-15","conditions":"High Dosage Buprenorphine","enrollment":60},{"nctId":"NCT03015246","phase":"PHASE1, PHASE2","title":"Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2016-12","conditions":"Heroin Dependence, Opioid Use Disorder","enrollment":26},{"nctId":"NCT03028883","phase":"","title":"Buprenorphine Dose Adjustments and Gestational Age","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2016-12-02","conditions":"Neonatal Abstinence Syndrome","enrollment":40},{"nctId":"NCT00941304","phase":"PHASE2","title":"Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain","status":"COMPLETED","sponsor":"BioDelivery Sciences International","startDate":"2009-08","conditions":"Dental Pain","enrollment":153},{"nctId":"NCT02559973","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-09","conditions":"Opioid Use Disorder","enrollment":47},{"nctId":"NCT00315341","phase":"PHASE4","title":"Starting Treatment With Agonist Replacement Therapies (START)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-04","conditions":"Opiate-related Disorders","enrollment":1269},{"nctId":"NCT03002961","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-6000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-07","conditions":"Opioid Use Disorder","enrollment":48},{"nctId":"NCT00710385","phase":"PHASE3","title":"Abuse Liability of Suboxone Versus Subutex","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opioid-related Disorders","enrollment":19},{"nctId":"NCT01296334","phase":"NA","title":"Analgesic and Antihyperalgesic Effects of Morphine and Buprenorphine","status":"COMPLETED","sponsor":"mads u werner","startDate":"2011-02","conditions":"Pain","enrollment":34},{"nctId":"NCT01903005","phase":"PHASE4","title":"Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2013-07","conditions":"Opioid Dependence, on Agonist Therapy","enrollment":668},{"nctId":"NCT01285856","phase":"NA","title":"Hair Testing to Assess Consumption of Illicit Psychotropic Agents and Alcohol by Patients Treated With High-dose Buprenorphine and Methadone. Search for a Pharmacogenetic Contribution to Low Efficacy of Substitution Medications","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2010-08","conditions":"Substance Abuse","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"High Dose Buprenorphine","genericName":"High Dose Buprenorphine","companyName":"Rutgers, The State University of New Jersey","companyId":"rutgers-the-state-university-of-new-jersey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose buprenorphine is a partial mu-opioid receptor agonist that provides stronger analgesia and opioid dependence treatment at elevated doses compared to standard formulations. Used for Moderate to severe chronic pain, Opioid use disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}